Pamalican Asset Management Ltd Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Pamalican Asset Management Ltd acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 6,900 shares of the biopharmaceutical company's stock, valued at approximately $4,915,000. Regeneron Pharmaceuticals accounts for about 2.2% of Pamalican Asset Management Ltd's holdings, making the stock its 16th biggest position.

A number of other hedge funds and other institutional investors have also made changes to their positions in REGN. OFI Invest Asset Management purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. raised its position in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares in the last quarter. Avalon Trust Co acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $36,000. Crowley Wealth Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $36,000. Finally, Private Wealth Management Group LLC grew its holdings in shares of Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 39 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded down $12.39 during midday trading on Wednesday, hitting $544.42. The company had a trading volume of 776,524 shares, compared to its average volume of 695,639. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $59.52 billion, a PE ratio of 14.26, a P/E/G ratio of 2.34 and a beta of 0.44. The firm has a 50-day moving average price of $669.26 and a 200-day moving average price of $766.90. Regeneron Pharmaceuticals, Inc. has a twelve month low of $526.17 and a twelve month high of $1,211.20.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $11.86 earnings per share. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's payout ratio is 2.30%.

Analyst Ratings Changes

Several equities analysts recently issued reports on REGN shares. BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 4th. UBS Group downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Bernstein Bank lowered their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. TD Cowen reduced their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a research report on Tuesday, February 4th. Finally, Wells Fargo & Company cut their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research note on Friday, January 10th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $966.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.